Interleukins areglycoproteins that belong to the group of cytokines. Most of the interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and end othelial cells. They are primarily responsible for regulating immune response in the body. In addition, they also regulate cell growth, differentiation, and motility.Poor regulation of interleukins has been implicated with development of many immune-mediated and inflammatory diseases. The interleukin inhibitors are the immunosuppressive agents that inhibit the action of interleukins andare used in various indications including asthma, eczema, gout, arthritis, psoriasis, systemic sclerosis, ankylosing spondylitis, and others. The interleukin inhibitors are interleukin antagonist monoclonal antibodies that mostly binds to the specific interleukins and inhibit its signaling activity. Rise in incidence of inflammatory diseases has brought an imperative demand for effective counter-measures. In the recent years, tremendous efforts in research have brought several interleukin inhibitors at various phases of development, with some promising to be beneficial in managing many immune-mediated and inflammatory diseases.
The global interleukin inhibitors market is expected to register a substantial growth in the near future attributed toincrease in prevalence of chronic inflammatory diseases such as arthritis, psoriasis, and asthma. Moreover, rise in awareness among people regarding chronic inflammatory diseases and their treatment further drives the growth of the market. However, side-effects and high cost associated with the biologics restrain the growth of the market. In contrast, presence of a strong product pipeline by various key players are expected to provide lucrative opportunities for the growth of interleukin inhibitor market.
The interleukin inhibitor market is segmented on the basis of application, type, distribution channel and region. The applications covered in the study include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, transplant rejection and others. By type, the market is dividedintoIL-17 inhibitors, IL-23 inhibitors, IL-1 inhibitors, IL-5 inhibitor, IL-6 inhibitors, IL-2 inhibitors, and others. On the basis of distribution channel, the market is classified into hospital pharmacies, retail pharmacies, online pharmacies, and research institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The report provides a comprehensive analysis of the key players of the interleukin inhibito rmarket including AbbVie, AstraZeneca plc, Eli Lily and Company,F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc,Investor AB (Swedish Orphan Biovitrum AB), Johnson & Johnsons, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd.
Key Benefits For Stakeholders
This report provides a detailed quantitative analysis of the current interleukin in hibitors market trends and futureestimations which assists to identify the prevailing opportunities.
An in-depth interleukin inhibitors market analysis includes various countries, and is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate country-specific plans.
A comprehensive analysis of the factors that drives and restrains the growth of the global interleukin inhibitors market is provided.
Region-wise market conditions are comprehensively analyzed in this report.
An extensive analysis of various countries provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the interleukin inhibitors market are profiled in this report and their strategies are analyzed thoroughly, which help to understand the competitive outlook of the market.
Interleukin Inhibitors Market Report Highlights
By Distribution Channel
Key Market Players
Johnson & Johnsons, GlaxoSmithKline Plc, Sanofi SA, Eli Lily and Company, AbbVie, Regeneron Pharmaceuticals Inc., Novartis AG, AstraZeneca plc, Investor AB (Swedish Orphan Biovitrum AB), F. Hoffmann-La Roche Ltd.